Search This Blog:    HIV   MPOX

DeutschEspaƱolFrançaisItaliano

 


Gilead's $21 Billion Deal Splurge May End in Regret

Gilead Pharmaceuticals Inc. has faced the same problem for years: The drugmaker has a strong core business in its world-leading HIV franchise, but it ...


View article...

Top stories of the last 30 days